VPN Plus+ ExclusiveLess Fear, More Hope: How Research is Driving New Strategies in Hemangiosarcoma Treatment and PreventionDecember 11, 2025In this session: Antonella Borgatti, DVM, MS, DACVIM (Oncology), DECVIM-CA, enlightens attendees with original research from the University of Minnesota on eBAT, a first-in-class bispecific targeted angiotoxin. eBAT is designed to selectively eliminate tumor cells and tumor-initiating cells, offering dual potential as both a therapeutic and preventive option in high-risk canine populations.
SPONSORED CONTENTFast Itch Relief for Canine PatientsA treatment for allergic and atopic dermatitis, given just once a day. Visibly improves itch fast. + Learn More Now
VPN Plus+ ExclusiveIntroduction to Oncology: Easy Peasy BasicsMay 12, 2023This session: Lindsay Hallman, VTS, touches on the history of cancer, and chemotherapy, as well as the modern use of chemotherapy in veterinary medicine. The second half of the lecture focuses on common oncological emergencies, hemangiosarcoma, osteosarcoma, mast cell tumors, and lymphoma.
University of Minnesota develops cancer drug that helps dogs with hemangiosarcomaFebruary 14, 2017The University of Minnesota has announced the breakthrough trial of a new drug that improves survival rates in dogs diagnosed with a cancer called hemangiosarcoma (HSA). The research and results were published recently published in the journal of Molecular Cancer Therapeutics.
